Microorganisms (Basel), 2022-02, Vol.10 (2), p.433
2022
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Two-Drug Regimens for HIV-Current Evidence, Research Gaps and Future Challenges
- Ist Teil von
- Microorganisms (Basel), 2022-02, Vol.10 (2), p.433
- Ort / Verlag
- Switzerland: MDPI AG
- Erscheinungsjahr
- 2022
- Quelle
- EZB Free E-Journals
- Beschreibungen/Notizen
- During the last 30 years, antiretroviral treatment (ART) for human immunodeficiency virus (HIV) infection has been continuously evolving. Since 1996, three-drug regimens (3DR) have been standard-of-care for HIV treatment and are based on a protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI) plus two nucleoside reverse transcriptase inhibitors (NRTIs). The effectiveness of first-generation 3DRs allowed a dramatic increase in the life expectancy of HIV-infected patients, although it was associated with several side effects and ART-related toxicities. The development of novel two-drug regimens (2DRs) started in the mid-2000s in order to minimize side effects, reduce drug-drug interactions and improve treatment compliance. Several clinical trials compared 2DRs and 3DRs in treatment-naïve and treatment-experienced patients and showed the non-inferiority of 2DRs in terms of efficacy, which led to 2DRs being used as first-line treatment in several clinical scenarios, according to HIV clinical guidelines. In this review, we summarize the current evidence, research gaps and future prospects of 2DRs.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 2076-2607eISSN: 2076-2607DOI: 10.3390/microorganisms10020433Titel-ID: cdi_doaj_primary_oai_doaj_org_article_49dcef01c97545b795957a32881641dd
- Format
- –
- Schlagworte
- Acquired immune deficiency syndrome, AIDS, anti-retroviral treatment (ART), Antiretroviral agents, Antiretroviral therapy, Cardiovascular disease, Clinical trials, Drug interactions, Drug resistance, HIV, Human immunodeficiency virus, human immunodeficiency virus (HIV), Life expectancy, Life span, Non-nucleoside reverse transcriptase inhibitors, Nucleoside reverse transcriptase inhibitors, Nucleosides, Patients, Protease inhibitors, Proteinase inhibitors, Review, RNA-directed DNA polymerase, Side effects, three-drug regimen (3DR), Toxicity, two-drug regimen (2DR)